Article

China's regulatory body approves STAAR Surgical's ICL for myopia

STAAR Surgical Co. received approval by the People’s Republic of China’s State Food and Drug Administration (SFDA) to market the STAAR Visian implantable collamer lens (ICL) as a treatment for myopia.

STAAR Surgical Co. received approval by the People’s Republic of China’s State Food and Drug Administration (SFDA) to market the STAAR Visian implantable collamer lens (ICL) as a treatment for myopia.

“This approval is an important achievement for STAAR. It will allow us to enter a market that we believe has the potential to become one of the largest markets for the Visian ICL,” said David Bailey, president and CEO of STAAR Surgical. “Currently, China is the second largest market in the world for the LASIK procedure and there is a higher rate of incidence for myopia and astigmatism in Asian countries compared with the rest of the world. With these two market dynamics, we believe that successful entry into this market could lead to meaningful growth in our overall refractive business.”

Bailey added that a training center and regional distribution operation have been established, and was hopeful that the SFDA would approve the Visian Toric ICL by the end of the year.

“The SFDA’s approval [of Visian ICL] is an important milestone for the correction of myopia in our country,” said Professor Shen Ye, Zheyi Eye Center, Hangzhou, China. “The ICL allows the patient the opportunity to acquire excellent natural vision. Our clinic research indicates that the ICL has very high patient satisfaction levels.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.